An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.

Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.

The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.